HCM
HUMA icon

Hollencrest Capital Management’s Humacyte HUMA Stock Holding History

Hollencrest Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000
Closed -$10.9K – 1192
2024
Q3 		$10.9K Hold
2,000
– – ﹤0.01% 746
2024
Q2 		$9.6K Buy
+2,000
New +$10.4K ﹤0.01% 751

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hollencrest Capital Management's HUMA Position: Q4 2024 in Review

Hollencrest Capital Management sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 2,000 shares — an estimated $10.9K sold.

Hollencrest Capital Management first reported a position in HUMA in Q2 2024 and held it in 2 quarters. The position peaked at $10.9K in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • Hollencrest Capital Management reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • Hollencrest Capital Management sold 2,000 Humacyte shares in Q4 2024, an estimated $10.9K.
  • Hollencrest Capital Management first reported a position in Humacyte in Q2 2024 and held it in 2 quarters.
  • Hollencrest Capital Management's Humacyte position peaked at $10.9K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on Hollencrest Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.